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In recent years, an approach called “chemical genetics” has
been adopted in drug research to discover and validate new tar-
gets and to identify and optimize leads by high throughput
screening. In this work, we tested the ability of a library of small
peptidomimetics to induce phenotypic effects with functional
implications on a panel of strains of the budding yeast Saccha-
romyces cerevisiae, both wild type and mutants, for respiratory
function and multidrug resistance. Further elucidation of the
function of these peptidomimetics was assessed by testing the
effects of the compound with the most prominent inhibitory
activity, 089, on gene expression using DNAmicroarrays. Path-
way analysis showed the involvement of such a molecule in
inducing oxidative damage through alterations in mitochon-
drial functions. Transcriptional experiments were confirmed by
increased levels of ROS and activation of mitochondrial mem-
brane potential. Our results demonstrate the influence of a
functional HAP1 gene in the performance of S. cerevisiae as a
model system.
Pharmaceutical and biotechnological fields are constantly
looking for new drugs characterized by innovation and econ-
omy (1). New approaches emerging from chemical and biolog-
ical knowledge, such as “chemical genetics” (2), consist of the
study of biological systems by systematic investigation of the
effects of small molecules on a specific cellular model rather
than perturbing with genemutations (3–5). This new approach
has been divided into forward and reverse chemical genetics;
the former is based on the research of a desired phenotypic
effect following the administration of small molecules to bio-
logical systems of interest, whereas the latter is based on the
investigation of the effects of small molecules against a specific
target (6–8). Tomake these new approaches time- andmoney-
saving, the set-up of easy, rapid, and economical chemical
synthesis and biological screening processes is essential (9, 10).
The budding yeast Saccharomyces cerevisiae, which has been
defined as an “honorarymammal” (11), is a suitablemodelorgan-
ism for this aim, mainly because of the high degree of conser-
vation with human cells concerning main biological processes
(11). Thanks to its ease of manipulation, it can be successfully
used to identify molecules of pharmacological interest (4, 12).
Moreover, once active compounds have been selected, func-
tional information about their mode of action can be inferred
from screening 5000 viable yeast haploid deletion mutant
strains for hypersensitivity or hyperresistance to eachmolecule,
thus identifying pathways that influence the cellular response
to tested compounds (13–16). However, so far, chemical
genetic approaches have used only one genetic background,
that of laboratory strain S288c, which is limited by an accumu-
lation of genetic defects, such as the inability to sustain proper
respiratory metabolism of this strain (4, 17–19). In this work,
we selected a panel of strains in which it is possible to investi-
gate the influence of a library of molecules on growth rate, res-
piratory metabolism (HAP1), and multidrug-membrane func-
tion (ERG6, SNQ2, and PDR3).
Peptidomimetics (20) play a prominent role as candidate
compounds to induce phenotypic effects on biological systems.
In fact, side-chain recognition dominates biological interac-
tions of almost all cellular processes; thus, peptidomimetics,
initially developed for their property of preventing degradation
and improving oral bioavailability of peptide-based drugs, have
been envisaged as a tool for perturbing such interactions and
identifying protein function. Small peptide-based agents
have attracted wide interest as cancer-targeting and anti-
infective agents, and there is a need to develop new high affin-
ity and high specificity peptidomimetic or small molecule
ligands in such widespread pathologies. Success in this area
depends on the ability to create novel complex molecular struc-
tures of a peptidomimetic nature as tools for probing protein-pro-
tein interactions. Diversity-oriented synthesis (21) is the concept
of choice for the rapid exploration of the chemical space. Our
efforts are oriented to the development of efficient synthetic strat-
egies for the production of rigid and polyfunctional heterocyclic
templates using elements from the chiral pool, such as carbohy-
drates and amino acids, which guarantee a high stereochemical
and functional diversity (22–26). The library of small peptidomi-
metics herein taken into accountwas synthesized by focusing on a
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bicyclic scaffold based on the 6,8-dioxa-3-azabicyclo[3.2.1]octane
coreanddiverse substituents, inorder tohypothesizeaconnection
between specific groups and biological effects.
EXPERIMENTAL PROCEDURES
Molecules—In this study, a preconstituted library, composed
of bicyclic peptidomimetics, bicycles from tartaric acid and
amino acids (BTAa),3 was used for assays on selected yeast
strains (supplemental Table 1).
Yeast Strains andMedia—Threewild-type strainswere used:
W303 (MAT can1-100 ade2-1 his3-11,15 leu2-3,112 trp1-1,
ura3-1), BY4742 (MAT his3 leu2 lys2 ura3), and 0117. The
deletion strains used were BY4742snq2 (MAT his3 leu2 lys2
ura3 snq2::kanMX), BY4742pdr3 (MAT his3 leu2 lys2 ura3
pdr3::kanMX4), and BY4742erg6 (MAT his3 leu2 lys2 ura3
erg6::kanMX4). Yeast strains used to simulate theHAP1pattern
of BY4742 were FY2607 (MATa ura3 his3 leu2 lys2-128TM
hap1T), FY2609 (MATaura3 his3 leu2 lys2-128TM) andFY2611
(MATa ura3 his3 leu2 lys2-128TM hap1:kanMX4). For growth
inhibition tests, yeast cells were inoculated at 1 105 cells/ml in
YPDmedium(yeastpeptonedextrose, yeast extract 1% (w/v), pep-
tone 2% (w/v), buffered at pH 4.8 with acetic acid, 2% glucose).
First Level Assays—First level assays allowed the selection of a
restricted number of active molecules. W303 and 0117 strains
were grown in YPD. The different cultures were dispensed at
equal volume onto 96-well plates, each well containing a differ-
ent compound at a concentration of 0.1 mM. The assay plates
were incubated at 28 °C with shaking, and yeast growth was
scored by measurement of A650 with a Victor high throughput
microplate spectrophotometer equipped with a 96-well plate
reader (PerkinElmer Life Sciences) every 2 h for the first 24 h
and then once a day for 7 days. Compounds responsible for the
variation in cell growth during the exponential phase or in the
OD650 value of the stationary phase or both were selected for
further characterization. These compounds were tested at con-
centrations of 1, 0.5, 0.4, 0.3, 0.2, and 0.1 mM.
Second Level Assays—Second level assays were carried out to
give more insight into the results obtained from the first run of
assays.Molecules selected because of their significant effects on
the wild-type strains at the concentration of 0.3mMwere tested
on BY4742erg6, BY4742snq2, and BY4742pdr3 strains.
Strains were grown in YPD supplemented with the molecule at
0.3 mM concentration and monitored with the same protocol
applied in the first level assay.
Normalization of OD650 Values—The OD650 values used
to define the growth curves were evaluated as the difference
between OD650 at tx and OD650 at t0. The percentage effect
of each molecule (% effect) was calculated as a function of
the OD650 value of treated cells in the stationary phase
(OD650st.ph.treat) and the OD650 of untreated cells in the stationary
phase (OD650st.ph.ctrl).
% effect
OD650
st.ph.treat OD650
st.ph.ctrl
OD650
st.ph.ctrl  100 (Eq. 1)
Determination of the Minimum Inhibitory Concentration
(MIC)—Wild-type strains (W303 and BY4742) were grown in 2
ml of YPD (pH 4.8) supplemented with the most active com-
pound, 089 ((7R)-3-benzhydryl-2-oxo-5-phenyl-6,8-dioxa-3-
aza-bicycle[3.2.1]octane-7-carboxyl-ethylamide), at concen-
trations of 1, 0.5, 0.4, 0.3, 0.2, and 0.1 mM. The assay cultures
were incubated at 28 °C with shaking. After 3 days, the concen-
tration of the cells was determined, and 100 cells were plated
(100 cells/plate) on YPD agar (in two replicates). After 5 days,
colony-forming units were calculated, and the concentration-
effect curve of the treatment was plotted.
Determination of Survival Rate—This test was carried out
with the LIVE/DEAD yeast viability assay (Molecular Probes),
following the manufacturer’s instructions, and with the meth-
ylene blue assay determining the survival rate of the two wild-
type W303 and BY4742 strains and of the BY4742erg6,
BY4742snq2, and BY4742pdr3 strains. Cells were grown in
YPD supplementedwith089 at concentrations of 1, 0.5, 0.4, 0.2,
and 0.1 mM; a positive control was also carried out without the
compound. The assay cultures were incubated at 28 °C, and
after 2 and 4 h, aliquots were processed with the LIVE/DEAD
and methylene blue assays, permitting calculation of the sur-
vival rate (number of live cells counted 100/total number of
cells in the positive control culture).
Microarray Hybridization—Yeast microarrays were con-
structed as described previously (27). Yeast cells (BY4742,
BY4742erg6, and BY4742snq2 strains) were treated in YPD
(pH 4.8) supplemented with 089 at 0.2 mM concentration and
incubated at 28 °C with shaking for 4 h. RNA was extracted
from about 1 109 cells using the hot acid phenol/chloroform
protocol. RNAs were quantified spectrophotometrically using
Nanodrop and by measuring the absorbance at 230, 260, and
280 nm and then calculating the 260/230 and 260/280 ratios
and considering good data to be values of 1.8–2.2. RNA integ-
rity was checked by electrophoresis in 1% agarose gel stained
with ethidium bromide. RNAs from cells treated with 089
(labeled with Cy5) were compared with RNAs from cells grown
in YPD as the reference sample (labeled with Cy3) (CyDye
Mono-Reactive Dye Pack, Amersham Biosciences). The label-
ing method used was the indirect method described by DeRisi
(see the University of California San Francisco DeRisi labora-
tory Web site). Hybridization took place at 63 °C for 14–16 h.
Gene Expression Analysis—Fluorescent cDNA bound to the
microarray was detected with a GenePix 4000B microarray
scanner (Axon Instruments), using theGenePixPro6.1 software
package to quantify microarray fluorescence. The control mi-
croarray spot quality required the following features: 50% as the
minimum percentage of pixels for which the foreground inten-
sity was greater than the background intensity 2 S.D. values;
80 pixels as the minimum number of pixels; absence of satu-
rated pixels. Median values for the foreground and background
of each channel were normalized using the MIDAWWeb tool
(28). A -fold change cut-off of 1.5 filtered by variance coefficient
was used to select differentially expressed genes. Genes within
each group were examined for functional enrichment using
Gene Ontology categories.
Pathway Analysis—Normalized transcriptional data were
analyzed with Eu.Gene Analyzer 5.1 (29), using Fisher’s exact
3 The abbreviations used are: BTAa, bicycles from tartaric acid and amino
acids;MIC,minimum inhibitory concentration; FET, Fisher’s exact test; YPD,
yeast peptone dextrose; ROS, reactive oxygen species.
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test (FET) and then visualized with T-MEV 4.4 (30). This
approach describes each pathway as up- or down-regulated,
considering the relative number of up- or down-regulated
genes annotated to that pathway and the result of the FET, false
discovery rate-corrected, for the same pathway. In our analysis,
we included yeast pathways from the KEGG (31), Reactome
(32), and YOUNG (lists of target genes for known transcription
factors) (33) databases. Transcriptional data of deletionmutant
strainswere obtained from theRosetta compendium (34). Clus-
tering of pathway-based analysis of microarray data was per-
formed according to the procedure described in Ref. 35.
Fluorescence Microscopy—After 4 h of treatment with 089
at 0.2 mM concentration, or without it as a control, cultured
cells were resuspended at 1  106 cells/ml in 10 mM HEPES
buffer, pH 7.4, containing 5% glucose. Rhodamine B hexyl ester
(Molecular Probes) was added to a final concentration of 100
nM. After 15–30 min of incubation, the mitochondrial mem-
brane potential was visualized by fluorescence microscopy (ex-
citation at 555nm, green; emission at 579nm, red). An equal
aliquot of cells was treatedwith dihydrorhodamine 123 (Molec-
ular Probes) to analyze endogenous reactive oxygen species
(ROS) production, observed after 60 min of incubation (excita-
tion  at 505 nm, blue; emission  at 534 nm, green). Each
aliquot was treated with Calcofluor White (M2R) (blue) to
show the cell wall in order to count total cells.
RESULTS
Selection of the Panel of Strains—Several easily detectable
phenotypes in the yeast cell are related to growth rate, respira-
tory metabolism, and cell wall-multidrug resistance. The panel
of strains of the budding yeast we have selected encompasses
S. cerevisiae wild type for respiratory function and multidrug
resistance, two laboratory strains, W303 and FY2609, and one
wine strain, 0117. We probed the effect of the molecules on
respiration by using strains altered in the respiratory function,
BY4742 and FY2607, that harbor a mutation caused by a trans-
poson in the HAP1 coding sequence that reduces Hap1p func-
tion by 75% (4, 17–19). This mutation was studied alone and
in combination with other deficiencies in genes involved in
cell wall and multidrug resistance (erg6, snq2, and
pdr3). Erg6p is a sterol 24C-methyl transferase, which is
involved in the synthesis of ergosterol; Snq2p is a drug efflux
pump belonging to the family of the ATP-binding cassette
transporters, conferring resistance to many drugs and oxygen
radicals; Pdr3p is a zinc finger protein, a transcriptional co-
activator (in association with Pdr1p) of genes encoding ATP-
binding cassette transporters.
First Level Assays—The effects of 104 compounds, compos-
ing a preconstituted library, each at 0.1mM concentration, were
initially tested onW303 and 0117wild-type strains. Thesemol-
ecules (supplemental Table 1), which are both secondary and
tertiary amides based on the 6,8-dioxa-3-azabicyclo[3.2.1]-oc-
tane scaffold (Table 1), were synthesized as described previ-
ously (22–26).
Because the two strains showed the same fitness behavior
after treatment with the molecules, indicating that the
higher membrane permeability associated with 0117 did not
affect the drug effects, we referred in the other assays toW303
only. One of the tested compounds induced a growth rate
increase between 10 and 20%, whereas 22 compounds resulted
in a decrease between 10 and 20%, and six molecules resulted
in a decrease between 20 and 50% of growth rate (supple-
mental Table 2). Thus, higher concentrations (1 and 0.5 mM) of
the compounds inducing more than 10% growth decrease at a
concentration of 0.1 mM were tested. Effects of intermediate
concentration (0.4, 0.3, and 0.2 mM) of 16 molecules inducing a
more than 80% growth decrease in W303 were then investi-
gated (Table 2).
To gain insight into the effect of the molecules on funda-
mental cellular functions, second level assays were con-
ceived by testing the effect of the selected molecules on a
panel of deletion mutant strains constructed in the BY4742
genetic background, compared with the parental strain. Nota-
bly, molecules that were selected because of their ability to neg-
atively affect the growth rate ofW303 and 0117mostly induced
an increase or only a weak decrease in growth rate in BY4742.
This observation suggests that the different genetic back-
grounds of these two strains influenced the results. W303 and
BY4742 are highly genetically similar, although one of themost
striking differences is the presence of a transposon insertion in
the coding region of the HAP1 gene in the BY4742 strain. The
alteration in Hap1p function is known to reduce BY4742 respi-
ratory ability (4, 17–19). The effect of the 16 compounds that
induced a decrease between 10 and 20% in thewild-type genetic
context was further tested onBY4742erg6, BY4742snq2, and
BY4742pdr3 strains at a concentration of 0.3mM, which is the
minimum concentration that induced an effect on the wild-
type strain (Fig. 1). Five of the compounds tested,011,012,018,
022 and 028, decreased the growth rate ofW303, whereas they
showed no effects on BY4742 and an increase in BY4742snq2
and BY4742erg6mutant strains. This effect can be attributed
to an increase in the intracellular/cytoplasmic concentration
of themolecule, due to a defect in the efflux activity (deletion of
SNQ2) or to a higher membrane permeability (deletion of
ERG6). Four of the molecules tested were able to increase the
growth rate of BY4742. Specifically, 066 and 067 exerted the
same effect even on Pdr3p and Snq2p; 038 and 053 induced an
increase in growth rate even on Pdr3p, Snq2p, and Erg6p. Fur-
ther assays on 089, which was identified as themolecule induc-
ing the most intense cell growth decrease (more than 80%),
showed that after 18 h of treatment at 0.3 mM concentration,
the variation in OD650 value of the culture of BY4742erg6
became negative due to cell death, confirmed by microscopic
observation with LIVE/DEAD (live cells converting the green
fluorescent intracellular staining FUN1dye into red fluorescent
intravacuolar structures) and methylene blue (dead cells turn-
ing blue) assays as well as the presence of cellular debris.
Relationship between Molecular Structure and Biological
Effect—The screening conducted in this study was carried out
by treating a whole organism with small molecules. Analysis of
the observed effects provided information on the connection
between the molecular structure and the ability to perturb the
growth rate of treated cells, regardless of the target receptor of
eachmolecule. The class of molecules having the general struc-
ture III, as shown in Table 1 (106, 107, 108, 110, 111, 112, 113,
and 114) induced a growth rate decrease only if the molecule
Chemical Genetics of S. cerevisiae
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had a secondary amine as the R4 group. Themolecules contain-
ing a leucine isostere as the R1 group (119, 120, 123, and 124)
did not induce effects in any case. Phenotypic effects of com-
pounds having an ethyl group at R4, (020, 024, 025, 042, 049,
057, 072, 075, 076, 089, and 090) suggested that 1) the pres-
ence of a protic donor group (resulting in R4 hydroxyethyl res-
idue), which in some cases was connected to higher cell growth
rate, and 2) the substitution of themethyl groupwith CF3 at the
second position of the ethylamine was associated with a higher
growthdecrease, not attributable to the sterichindranceof fluo-
rine (similar to hydrogen) but to the ability to form polar inter-
actions. The ability of molecules having the general structure I,
as shown in Table 1 (056, 057, 058, 059, 060, 061, 066, 067,
068, 069, 070, and 071), to induce a biological effect was asso-
ciated with the steric hindrance of the R4 group; the lower the
steric hindrance, the higher the biological effect, decreasing up
to 50% in the presence of a bulkier group. On the contrary, the
opposite correlation was evident in molecules possessing the
scaffold II, as shown in Table 1 (001, 002, 004, 005, 008, 009,
010, 011, 012, 013, 014, 015, 016, and 018), thus suggesting
two different targets for the two compound classes. By compar-
ing 089with othermolecules of the library that differed in some
functional groups, a drastic decrease in the ability to induce a
biological effect was seen to be due to the lack of the carbonyl
group embedded in the bicycle, the benzhydryl group substitu-
tionwith a benzyl group, and the lipophilic R4 chain elongation.
Second Level Assays—TheMIC of 089 onW303 and BY4742
wild-type strains was determined (supplemental Fig. 1). Both
strains were characterized by a MIC of 1 mM, but the EC50
values, which were 0.25 mM for W303 strain and 0.38 mM for
BY4742 strain, were more interesting. The survival rate of the
strains W303, BY4742, BY4742erg6, BY4742snq2, and
BY4742pdr3 after a 2- and 4-h treatment with different con-
centrations of 089 (1, 0.5, 0.2, and 0.1 mM and control) was
evaluated. The results of this assay (Fig. 2) showed that at higher
concentrations, the molecule induced steady effects in each
strain even at the early time points. Lower concentrations (up
to 0.1 mM in the 2-h treatments and up to 0.2 mM in the 4-h
treatments) induced a survival percentage decrease only for
W303, thus confirming the MIC results. Each strain showed
almost the same higher survival decrease at 0.5 mM concentra-
tion of 089 (nearly 30% in the 2-h treatment, around 10% in the
4-h treatment). By contrast, BY4742 revealed itself to be the
most resistant to the treatment, as previously observed. The 4-h
exposure to 089 with a concentration of 1 mM triggered the
same effects on all of the tested strains, including BY4742. The
concentration of 089 inhibiting the growth of deletion mutant
strains induced a minor effect on BY4742, probably due to dif-
ferent respiratory ability.
Because the two wild-type tested strains, BY4742 andW303,
had a different genetic background, we further investigated the
role ofHAP1 using FY2609 (HAP1) and FY2607 (hap1T) as two
TABLE 1
Scheme of tested compounds
The tested library is composed of bicyclic peptidomimetics, BTAa (bicycles from tartaric acid and amino acids), which present all of the combinations of the R groups with
the three selected scaffolds. Bn, benzyl; Bzh, benzhydryl; s-Bu, sec-butyl; TBDMS, tert-butyldimethylsilyl; p-NO2-Ph, p-nitrophenyl; TFE, trifluoroethyl; nPr, propyl; Cyp,
cyclopropyl; Prg, propargyl; nBu, butyl; iAm, isoamyl; Hex, hexyl; Cyh, cyclohexyl; MBn, (S)--methylbenzyl; iPr, isopropyl; tBu, tert-butyl.
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additional strains having similar alterations of HAP1 in the
same genetic background. The FY strains (36) have a similar
pedigree and genetic background as the BY series strains, all
being derivatives of S288c; therefore, the results observed in
FY2607 can be reasonably generalized to BY4742. We treated
the FY strains with 089 at 0.3 mM concentration. We observed
an inhibition rate of 7% for FY2607 hap1T and of 8.9% for
FY2609 HAP1, and this difference was statistically significant
(p 0.05). These results confirmed theHAP1-associated trend
highlighted in the comparison between BY4742 and W303.
Specifically, compound 089 elicits stronger inhibiting effects in
the presence of thewild-typeHAP1 gene. To further investigate
the role of theHAP1 gene in combination with the other muta-
tions studied, we are planning to introduce the wild-type allele
into the BY4742 strain and into the three knock-out strains,
BYerg6, BYsnq2, and BYpdr3.
Transcriptional Analysis—Transcriptional analysis fol-
lowing the treatment with 089 at 0.2 mM concentration was
carried out on deletion mutant strains that in former assays
showed higher sensitivity to the treatment (BY4742erg6
and BY4742snq2) and on the parental strain (BY4742). We
chose to perform the transcriptional profiling in the pres-
ence of a molecule concentration having some effects on cell
viability but allowing survival of at least 50% of treated pop-
ulations, as determined by EC50 evaluation. We focused on
the laboratory type strains because a large quantity of pub-
licly available datamake this genetic background themost suit-
able for further comparisons of transcriptional profiles ob-
tained in this study with those present in public databases.
We analyzed the lists of differentially expressed genes obtained,
applying 1.5 as the -fold change threshold. The two deletion
mutants showed an overexpression of genes coding mitochon-
drial proteins or genes involved in respiration and in response
to oxidative stress, in contrast to BY4742. This strain also
showed down-regulation of genes encoding some mitochon-
drial F1F0-ATP synthase subunits (ATP1, ATP2, ATP3, ATP4,
and ATP16). The deleted strains showed increased expression
FIGURE 1. Treatment effects. Effects of molecules selected in the first level
assay tested at the concentration of 0.3 mM on BY4742erg6, BY4742snq2,
and BY4742pdr3were compared with BY4742. The effect of each molecule
was calculated as percentage variation of theOD650 of a cell culture grownon
YPD (pH 4.8) supplemented with molecule at various concentrations com-
pared with a cell culture grown on YPD (pH 4.8). Numbers used to designate
molecules refer to the position in the library. Error bars, S.D. values obtained
by three measures of the percentage of growth variation.
TABLE 2
Structures and effects of compounds selected from the first level
assay
Molecules were selected because of their ability to induce (at a concentration of 0.5
mM) a growth decrease more intense than 80% in W303 strain with respect to the
growth rate of the untreated strain. Numbers used to designate molecules refer to
the position in the library. The effect of each molecule was calculated as percentage
variation of the OD650 of a cell culture grown on YPD (pH 4.8) supplemented with
molecule at various concentrations in comparisonwith a cell culture grown on YPD
(pH 4.8). , variation  80%; , variation  50%; , variation 
20%;, variation 10%;, no effect.
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of some of the mitochondrial electron transport chain com-
plexes, such as nuclear genes coding for subunits of the cyto-
chrome c oxidase (COX9, COX5A, COX6, and COX13) and of
the succinate dehydrogenase (SDH1, SDH3, and SDH4) and a
mitochondrial porin (POR1).When comparing genes undergo-
ing a variation in expression levels exclusively in the deleted
strains, a largemajority of genes codingmitochondrial proteins
(NDE2, LSC2, ACS1, PPA2, CIT2, CIT3, etc.) or involved in
respiration (ETR1,QCR7,LSC2,MBR1, andPPA2) were detect-
able, and those genes were all overexpressed. Themacromolec-
ular complex disassembly (genes involved are SSB1, RSC3,
TPA1, YGL120C, and RSC58) was up-regulated in BY4742 but
down-regulated in BY4742snq2, thus showing no significant
variation in BY4742erg6. These results can be ascribed to an
increase in the intracellular concentration of the molecule,
depending on a decrease ofmembrane rigidity in the case of the
erg6mutant or on reduction of intracellular levels of the mol-
ecule by extrusion in the case of the snq2mutant. The higher
the intracellular concentration, the higher are the drug effects.
Because the two deleted strains herein investigated have the
same genetic background as BY4742,
the observation of overexpression of
genes involved in respiration and
response to oxidative stress only
in the deleted strains suggests that
the intracellular concentration of
the molecule in the wild-type strain
is reduced by active export mecha-
nisms. As a consequence, the effects
are more pronounced in deletant
strains. Every strain showed an
up-regulation of genes involved in
telomere maintenance and organi-
zation and in homeostatic processes
(YRF1-1, YRF1-2, YRF1-3, YRF1-4,
YRF1-5, YRF1-6, and YRF1-7), show-
ing instead a down-regulation of
genes involved in protein folding
and protein targeting to membrane
and to endoplasmic reticulum (SSA1,
SSA4, SSE1, SSE2, YDJ1, HSP82, and
KAR2), thus indicating that 089
induces cellular damage, as indicated
also by the up-regulation of telomere
maintenance and organization.
Pathway Analysis—Pathway anal-
ysis was used to assign a probability
of alteration in selected pathways
by using the FET p value as an in-
dication of the likelihood of the
involvement of a cellular compart-
ment or of a set of biological reac-
tions. Pathway analysis over our
selected set of pathways was carried
out using the FET (see “Experimen-
tal Procedures”). The Fisher’s test p
value, along with the state of regula-
tion of each pathway (described
considering the relative number of up- or down-regulated
genes annotated to that pathway) indicated the likelihood of its
involvement. The pathway analysis of transcriptional data con-
firmed the increase in respiratory deficiency, highly evident in
the BY4742erg6 strain, and of anaerobic respiration, espe-
cially of the electron acceptor reaction list and electron trans-
port chain, with an opposite trend in the wild-type strain. This
result confirmed the involvement of respiratory metabolism
and HAP1 function in response to 089, confirming HAP1 as
one of the targets.
We further used an advanced pathway approach to com-
pare the three experiments of this study with a collection of
publicly available experiments describing the effect on tran-
scription of selective gene deletions. This approach uses path-
way signatures to compare experiments at the pathway level
(35). We used this approach with a chemical genetic mindset,
asking which other deletion was phenocopied at a transcrip-
tional level by 089. If bootstrap-based clustering approaches of
the pathway signatures reveal similarity between the transcrip-
tional data of the treatment of yeast with 089 and the transcrip-
FIGURE 2. Survival rate after treatment with 089. a, survival rate of BY4742 strain; b, survival rate of W303
strain; c, survival rate of BY4742erg6 strain; d, survival rate of BY4742snq2 strain; e, survival rate of
BY4742pdr3 strain. White, 2-h treatment with 089; black, 4-h treatment. The yeast strain survival rates were
calculated as the number of live cells (by LIVE/DEAD and methylene blue assays) per 100 divided by the total
number of the same strain untreated. Values indicate the mean of twomeasurements, and error bars indicate
the corresponding S.D. values.
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tional data of a group of untreated deletion yeast strains, then it
is possible to hypothesize the molecular target at the pathway
level. Interestingly, by this comparison, it is possible to observe
a similarity between the effects of the treatment with molecule
089 and the effects of the two gene deletions erg4 and gas1
(Fig. 3). Both of these genes are involved in cell wall and mem-
brane assembly, the first encoding C-24(28) sterol reductase,
which catalyzes the final step in ergosterol biosynthesis, the
latter encoding -1,3-glucanosyltransferase, required for cell
wall assembly. The treatment with 089 and the deletion of
ERG4 showed up-regulation in the metabolism of glucose, car-
bohydrates, and small molecules and in glycolysis and gluconeo-
genesis and down-regulation in the oxidative branch of the
pentose phosphate pathway in methionine metabolism, meth-
ylation, and methyl donor molecule
biosynthesis. The treatment with
089 and the deletion of the GAS1
gene showed a down-regulation
of the complex involved in regu-
lating the histone gene transcrip-
tion (HIR2).
By probing enrichment for target
genes of specific transcription fac-
tors, we observed that 089 induces
an overregulation of genes con-
trolled by CIN5, a transcriptional
factor that mediates pleiotropic drug
resistance. Deletions of ERG4 and
GAS1 have an opposite transcrip-
tional effect on the CIN5 targets,
defining a transcriptional module
as affected by this treatment. The
effects induced by cell wall misassembly (even at the nuclear
level) seem to be more similar to those induced by the treat-
ment of wild-type yeast strain with 089 than those induced by
cell membrane misassembly. This suggests that the molecule
selected in this work targets a component of the cell wall and
consequently induces oxidative stress. Given that the wall is a
peculiar yeast structure not present in higher eukaryotic cells,
089 has great potential to act as a selective antifungal.
Effects of the Molecule on Mitochondria—In addition to
showing effects onmitochondria, transcriptional pathway anal-
ysis highlighted that the treatment with 089 induces up-regu-
lation of the breakdown of hydrogen peroxide to water and
molecular oxygen and of SKN7, a transcriptional factor
required for optimal induction of heat-shock genes in response
to oxidative stress. We then investigated the effects of 089 on
ROS accumulation and mitochondrial membrane potential
activation. Deletant strains BY4742erg6 and BY4742snq2
treated for 4 h with 089 at 0.2 mM concentration, after staining
with dihydrorhodamine 123, showed twice asmuchROS(22 and
12%, respectively) as the ROS of deletant untreated cultures (10
and 6%, respectively) (Fig. 4), confirming transcriptional anal-
ysis indications. The wild-type strain BY4742 did not show any
variation in ROS accumulation after treatment with 089.
The profile observed in ROS accumulation was confirmed
when evaluating mitochondrial activation. Cells of the deletant
strains stained with rhodamine B hexyl ester showed a 3-fold
increase in mitochondrial membrane potential activation (12
and 9%), comparedwith untreated cells (4 and 2%), whereas the
wild-type strain mitochondrial activation level did not change
in either treated or untreated cells (Fig. 4).
DISCUSSION
Yeast genetics, cell biology, andmolecular genetics have ben-
efited enormously from the presence of a well characterized set
of strains derived fromS288c genetic background. S288c is pro-
foundly different from other strains of the S. cerevisiae genus
(37–39). When using yeast in chemical genetics studies, the
extent to which a phenotype induced by a molecule is depen-
dent on the genetic backgroundof the S288c derivatives is yet to
be fully understood. The results presented herein demonstrate
FIGURE 3. Pathway signatures visualized with T-Mev 4.4. Pathway signatures were obtained with Eu.Gene
Analyzer 5.1, using FET and thenvisualizedwith T-MEV4.4. This is a significant selectionof thepathwayanalysis
and the relative sample cluster of transcriptional data of the treatment of yeast with 089. Up-regulated path-
ways are visualized in red, and down-regulated pathways are shown in green. Yeast pathways from the KEGG,
Reactome, and YOUNG databases were included in the analysis. The YOUNG list is composed of target genes
for known transcription factors.
FIGURE 4. Quantitative evaluation of ROS accumulation and mitochon-
dria activation. Wild-type strain cells (BY4742) and deletant strain cells
(BY4742erg6 and BY4742snq2) were treated for 4 h with 089 at 0.2 mM
concentration, and then the mitochondrial membrane potential was de-
tected by rhodamine B hexyl ester staining, and ROS accumulation was eval-
uated by dihydrorhodamine 123 staining. White, the percentage values cor-
responding to cells treated with 089; black, the percentage values of
untreated cells. Percentages were calculated as themean of the number of
stained cells over total cells in the optical field evaluated in triplicate.
Student’s t test was used to evaluate the data significance. *, p  0.05.
Error bars, S.D.
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the influence of a functional HAP1 gene in the performance
of S. cerevisiae as a model system and the importance of
using a panel of strains to investigate the effects of a library of
bioactive molecules. The set of strains used in this work sig-
nificantly broadens the ability to dissect the biological effects
of a selected family of molecules, thus circumventing the limi-
tations of the laboratory strain S288c. Our results show how a
combined use of the proposed panel of gene deletion strains
with alterations in the respiratory function or multidrug resis-
tance-cell wall function can ascribe the biological function of a
molecule to a specific set of biological processes, paving theway
to more insightful investigations. The selected peptidomimetic
089 induces more severe effects on the wild-type W303 strain,
having a functionalHAP1 gene, than on the laboratory BY4742
strain, having almost the same genetic background asW303 but
themutatedHAP1 gene, thus giving an indication of an involve-
ment of the respiratory metabolism in response to 089 pertur-
bation. This hypothesis is confirmed even by theHAP1-associ-
ated trend of the molecule effects on FY strains. The strain
FY2609 (HAP1) showed greater inhibition than FY2607
(hap1T). Nevertheless, the intensity effect is weaker on FY
strains than on theW303 strain, indicating that aHAP1-medi-
ated increase in the respiratory metabolism alters the effects of
089 in a genetic background-associated function. It is evident
that a number of other genetic differences between the strains
could have epistatic effects on this phenotype. Overall, consid-
ering the wide range and differences of effects exerted by the
treatmentwith089 ondifferent strains, the genetic background
of the strain used for the screening again turns out to be of
extreme relevance when evaluating the biological effects of
small molecules (Table 3).
The use of a pool of strains bearing deletions of genes
involved in membrane assembly or function enables the iden-
tification of effects that could be concealed by the membrane
permeation incapability of the molecule. This is suggested
by the opposite effect of 089 on yeast growing rate, which
decreases for deletant strains but increases for the wild-type
strain. Transcriptional analysis indicates the presence of an
important stress condition that occursmore prominently in the
deletion mutant strains, a variation that can be ascribed to a
higher ability of the molecule to permeate the cellular or mito-
chondrial membrane or to remain in the cell cytoplasm. The
activity of 089 in inducing an increase in respiratory deficiency
and anaerobic respiration is confirmed by pathway analysis of
transcriptional data, thus corroborating theHAP1 as one of the
targets. The induction of oxidative stress at the mitochondrial
level is confirmed by an increase in ROS accumulation and
mitochondrial membrane activation level.
The application of the novel pathway-based approach (35) to
compare 089 effects at the transcriptional level with those of a
pool of gene deletions is a powerful in silico simulation that
identifies response trends to different stimuli (the former a
molecule, the latter a gene function loss). Accordingly, we iden-
tified a similar trend between the treatment with 089 and the
deletion of GAS1 and ERG4, the former stricter and the latter
weaker, leading to localization of the first molecular target at
the cell wall level, with oxidative stress being a secondary effect.
The cell wall is a peculiar yeast structure; hence, it is an excel-
lent target for selective antifungal drugs.
The pathway signature-based approach used here holds
the promise of enabling the classification of bioactive mole-
cules based on their transcriptional pathway signatures and
the assessment of similarity of the effects of different mole-
cules based on the pathway profile. By taking advantage of all
of these findings, it was possible to identify 089 as a potential
selective antifungal.
Model organisms that have evolved in permissive laboratory
conditions may introduce a bias into the assessment of biolog-
ical functions of a molecule, derived from the accumulation of
genetic defects in laboratory strains (such as the improper res-
piratory metabolism). When using yeast to learn fundamental
lessons about cell biology or the mechanism of action of a mol-
ecule, often to be generalized to mammalian cells, it is funda-
mental to assess to what extent the observed phenotype can be
generalized to other yeasts of the same species. In this study, the
use of a panel of different strains has been fundamental to the
analysis of the relationship between the activity and the struc-
ture of thewhole peptidomimetic library and cell function, thus
providing important insights for optimization of its activity.
Acknowledgments—We are grateful to Dan Spatt for supplying the
FY strains, to Luca Beltrame for helpful discussion on pathways
analysis, and to Mary Forrest for linguistic editing. We also thank
Fondazione Giuseppe Tommasello Organizzazione Non Lucrativa
di Utilita` Sociale.
TABLE 3
Strains tested in assays with 089
The inhibition rate assay refers to the treatment with 089 at 0.3 mM concentration, whereas the transcriptional analysis, ROS production, and mitochondrial membrane
activation evaluations have been done using 089 at 0.2 mM concentration. Inhibition rates were calculated as the percentage of inhibition compared with the untreated
culture. The ROS production and mitochondrial membrane activation percentage values were calculated as the mean of the number of stained cells over total cells on the
optical field. NT, not treated.
Strain HAP1 type Inhibition rate MIC EC50 Transcriptional analysis
ROS
production
Mitochondrial membrane
activation
089 NT 089 NT
% mM mM % % % %
W303 HAP1 83 1 0.25
BY4742 hap1T 0.3 1 0.38 Yes 0 0 0 0
BY4742erg6 hap1T 19.3 Yes 22 10 12 4
BY4742snq2 hap1T 2.6 Yes 12 6 9 2
BY4742pdr3 hap1T 1.9
FY2607 hap1T 7
FY2609 HAP1 8.9
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